JPRN-UMIN000025452已完成1 期
Phase I clinical study of a WT1-W10 peptide immunotherapy combined with standard treatment against diffuse midline glioma (WT1-TR-DMG). - WT1-W10 immunotherapy against DMG (WT1-TR-DMG)
Cancer Vaccination Therapy Research Network Central Office, Department of Immunology, Kochi Medical School0 个研究点目标入组 10 人开始时间: 2017年1月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3years-old 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •One or more of the following criteria leads to exclusion of the subject. 1)Uncontrollable infections, including active tuberculosis 2)Severe comorbidities (e.g. malignant hypertension, severe congestive heart disease, severe ischemic heart disease, myocardial infarction within 3 months, end-stage liver insufficiency, uncontrollable diabetes mellitus, severe pneumonitis etc.) 3)After the bone marrow implantation 4)Severe psychological disorders 5)Being enrolled in other clinical trials 6)Once enrolled in this study, but was disqualified for some reasons (Double enrollment is prohibited.) 7)Disqualified by the doctors due to some medical, psychological and/or social problems
研究者
相似试验
已完成
不适用
Phase I/II clinical study of WT1 peptide-based immunotherapy combined with Imatinib for chronic myelogeneous leukemiaJPRN-UMIN000003508Department of Cancer immunotherapy, Osaka University Graduate School of Medicine30
已完成
1 期
A pilot trial of immunotherapy with WT1 peptide vaccine for pediatric patients with bone or soft tissue sarcoma following conventional chemotherapy.Osteosarcoma Soft tissue sarcoma neuroblastoma Pediatric bone, soft tissue sarcoma at high risk of recurrence.JPRN-UMIN000005312Osaka Universty22
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine for the HLA-A*0201 positive patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000000933Department of Cancer immunotherapy, Osaka University Medical School10
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with malignant glioma.Malignant GliomaJPRN-UMIN000003504Department of Cancer immunotherapy, Osaka University Graduate School of Medicine3
尚未招募
不适用
Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for pediatric patients with malignant glioma.High grade glioma, Diffuse intrinsic pontine gliomaJPRN-UMIN000013257Osaka University Graduate School of Medicine Pediatrics18